Viridian Therapeutics, Inc. (VRDN) Misses Q2 EPS by 1c

Viridian Therapeutics, Inc. (NASDAQ: VRDN) reported Q2 EPS of ($1.27), $0.01 worse than the analyst estimate of ($1.26). Revenue for the quarter came in at $70 thousand versus the consensus estimate of $254 thousand.

For earnings history and earnings-related data on Viridian Therapeutics, Inc. (VRDN) click here.

You May Also Be Interested In

• SanDisk and Micron surge as Apple confirms memory price pass-through
• FedEx (FDX) PT Lowered to $424 at Bernstein SocGen Group
• Kroger (KR) Reports In-Line Q1 EPS, Beats on Revenue; Offers FY27 EPS Guidance